MAYNE PHARMA GROUP LIMITED - Announcements

Market Cap $398.1M Add to my watchlist

Healthcare

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused... Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.More

RCE'S BREAKTHROUGH

Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department of Defense...

Announcements

Filter Results

All Price Sensitive Only

MYX	Chairman and CEO's Addresses to Shareholders	PRICE SENSITIVE	24/11/20	3.27MB	Share
MYX	Mayne Pharma Board Renewal		09/11/20	149.61KB	Share
MYX	New data on Mayne Pharma's TOLSURA presented at IDWeek 2020		26/10/20	201.14KB	Share
MYX	Lapse of rights and AGM Notice of Meeting clarification		23/10/20	183.73KB	Share
MYX	Becoming a substantial holder		14/10/20	680.76KB	Share
MYX	2020 Annual General Meeting		14/10/20	1.61MB	Share
MYX	Appendix 4G		08/10/20	240.06KB	Share
MYX	2020 Corporate Governance Statement		08/10/20	559.51KB	Share
MYX	Annual Report to shareholders		08/10/20	3.76MB	Share
MYX	Mayne Pharma provides update on Women's Health pipeline	PRICE SENSITIVE	06/10/20	153.98KB	Share
MYX	Appendix 3G		29/09/20	215.73KB	Share
MYX	Mayne Pharma appoints new CFO		29/09/20	112.88KB	Share
MYX	Appendix 3G		22/09/20	715.91KB	Share
MYX	Change of Director's Interest Notice		02/09/20	199.03KB	Share
MYX	Change of Director's Interest Notice		01/09/20	203.1KB	Share
MYX	Ceasing to be a substantial holder		25/08/20	533.4KB	Share
MYX	Change in substantial holding		24/08/20	946.03KB	Share
MYX	2020 Full Year Investor Presentation	PRICE SENSITIVE	21/08/20	6.13MB	Share
MYX	2020 Full Year Media Release	PRICE SENSITIVE	21/08/20	404.79KB	Share
MYX	Appendix 4E and Statutory Accounts	PRICE SENSITIVE	21/08/20	1.59MB	Share
MYX	Change in substantial holding		07/07/20	922.46KB	Share
MYX	Mayne Pharma announces strategic partnership with Novast	PRICE SENSITIVE	06/07/20	158.24KB	Share
MYX	MYX announces FDA filing acceptance of E4/DRSP in the US	PRICE SENSITIVE	24/06/20	149.82KB	Share
MYX	Lapse of unlisted employee performance rights		15/06/20	167.92KB	Share
MYX	S&P DJI Announces June 2020 Quarterly Rebalance	PRICE SENSITIVE	12/06/20	223.16KB	Share
MYX	Becoming a substantial holder		03/06/20	405.74KB	Share
MYX	Ceasing to be a substantial holder		01/06/20	406.72KB	Share
MYX	MYX signs license agreement for contraceptive in Australia	PRICE SENSITIVE	28/05/20	150.15KB	Share
MYX	Becoming a substantial holder		25/05/20	433.44KB	Share
MYX	Mayne Pharma submits NDA for E4/DRSP to the FDA	PRICE SENSITIVE	16/04/20	121.21KB	Share
MYX	Change of CFO and Company Secretary		20/03/20	150.13KB	Share
MYX	Change in substantial holding		16/03/20	265.86KB	Share
MYX	Change of Director's Interest Notice		11/03/20	205.02KB	Share
MYX	Change of Director's Interest Notice		03/03/20	205.27KB	Share
MYX	Lapse of employee options and rights		02/03/20	163.09KB	Share
MYX	2020 Half Year Investor Presentation	PRICE SENSITIVE	21/02/20	3.5MB	Share
MYX	2020 Half Year Media Release	PRICE SENSITIVE	21/02/20	325.33KB	Share
MYX	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/20	1.11MB	Share
MYX	Change of Director's Interest Notice		09/01/20	276.03KB	Share
MYX	Change of Director's Interest Notice		09/12/19	284.37KB	Share
MYX	Employee LTI changes and Appendix 3B		09/12/19	422.23KB	Share
MYX	Final Director's Interest Notice		25/11/19	88.42KB	Share
MYX	Results of Meeting		22/11/19	165.85KB	Share
MYX	2019 AGM Presentation		22/11/19	705.16KB	Share
MYX	2019 AGM CEO's Speech	PRICE SENSITIVE	22/11/19	138.92KB	Share
MYX	2019 AGM Chairman's Address		22/11/19	116.24KB	Share
MYX	Mayne Pharma continues expansion of dermatology pipeline		19/11/19	103.55KB	Share
MYX	Mayne Pharma completes E4/DRSP transaction and Appendix 3B		13/11/19	346.94KB	Share
MYX	E4/DRSP contraceptive presented at EU gynecology conference	PRICE SENSITIVE	23/10/19	110.39KB	Share
MYX	Retirement of Director		21/10/19	102.92KB	Share
MYX	Notice of Annual General Meeting/Proxy Form		21/10/19	748.91KB	Share
MYX	Change of Director's Interest Notice (x2)		18/10/19	200.5KB	Share
MYX	Appendix 4G and Corporate Governance Statement		14/10/19	456.52KB	Share
MYX	2019 Annual Report		14/10/19	2.93MB	Share
MYX	Appendix 3B		03/10/19	294.07KB	Share
MYX	MYX signs license agreement for novel oral contraceptive	PRICE SENSITIVE	02/10/19	126.01KB	Share
MYX	Appendix 3B		30/09/19	296.05KB	Share
MYX	Lapse of employee options		16/09/19	160KB	Share
MYX	PBS listing for KAPANOL in chronic breathlessness		27/08/19	120.89KB	Share
MYX	2019 Full Year Results Investor Presentation	PRICE SENSITIVE	23/08/19	1.14MB	Share
MYX	2019 Full Year Results Media Release	PRICE SENSITIVE	23/08/19	174.98KB	Share
MYX	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	23/08/19	1.71MB	Share
MYX	Change in substantial holding		30/07/19	249.4KB	Share
MYX	Lapse of employee options		04/07/19	152.94KB	Share
MYX	Change in substantial holding		21/05/19	159.5KB	Share
MYX	Mayne Pharma market update	PRICE SENSITIVE	14/05/19	286.05KB	Share
MYX	Mayne Pharma investor presentation to Goldmans conference		04/04/19	5.02MB	Share
MYX	Change in substantial holding		14/03/19	342.74KB	Share
MYX	2019 Half Year Investor Presentation	PRICE SENSITIVE	22/02/19	1.44MB	Share
MYX	2019 Half Year Media Release	PRICE SENSITIVE	22/02/19	439.98KB	Share
MYX	Half Year Accounts	PRICE SENSITIVE	22/02/19	1.44MB	Share
MYX	Mayne Pharma announces new indication for Kapanol by TGA		19/02/19	419.43KB	Share
MYX	Lexette (halobetasol) foam now launched in the US		13/02/19	257.82KB	Share
MYX	Tolsura (SUBA-itraconazole) capsule now launched in the US	PRICE SENSITIVE	30/01/19	455.75KB	Share
MYX	Change of Director's Interest Notice		31/12/18	323.39KB	Share
MYX	Employee option exercise		28/12/18	251.6KB	Share
MYX	Change of Director's Interest Notice		24/12/18	354.14KB	Share
MYX	MYX extends debt facility and adds receivables facility		20/12/18	262.93KB	Share
MYX	MYX announces US commercial rights for SUBA-itra in BCCNS		18/12/18	413.5KB	Share
MYX	Ceasing to be a substantial holder		14/12/18	19.36KB	Share
MYX	FDA approval of Tolsura (SUBA-itraconazole) capsules	PRICE SENSITIVE	12/12/18	409.5KB	Share
MYX	Change of Director's Interest Notice		10/12/18	759.78KB	Share
MYX	Appendix 3B		07/12/18	412.44KB	Share
MYX	Becoming a substantial holder		06/12/18	164.69KB	Share
MYX	Final Director's Interest Notice		29/11/18	720.26KB	Share
MYX	Results of 2018 AGM		29/11/18	386.07KB	Share
MYX	2018 AGM CEO's Speech	PRICE SENSITIVE	29/11/18	256.36KB	Share
MYX	2018 AGM Chairman's Address	PRICE SENSITIVE	29/11/18	257.21KB	Share
MYX	Appendix 3B		31/10/18	693.61KB	Share
MYX	Retirement of Director		29/10/18	246.73KB	Share
MYX	Notice of Annual General Meeting / Proxy Form		29/10/18	2.75MB	Share
MYX	Investor Presentation Acquisition of halobetasol foam		26/10/18	660.17KB	Share
MYX	MYX announces acquisition of FDA approved halobetasol foam		26/10/18	425.89KB	Share
MYX	Appendix 4G and 2018 Corporate Governance Statement		19/10/18	1.22MB	Share
MYX	2018 Annual Report		12/10/18	5.1MB	Share
MYX	Appendix 3B, employee option exercise and option lapse		10/10/18	1.02MB	Share
MYX	Change in substantial holding		09/10/18	253.66KB	Share
MYX	Appendix 3B, employee option exercise and option lapse		11/09/18	816.24KB	Share
MYX	Change in substantial holding		31/08/18	354.01KB	Share
MYX	2018 Full Year Results Investor Presentation	PRICE SENSITIVE	24/08/18	1.43MB	Share

MYX Chairman and CEO's Addresses to Shareholders
24/11/20	PRICE SENSITIVE	3.27MB	Share
MYX Mayne Pharma Board Renewal
09/11/20		149.61KB	Share
MYX New data on Mayne Pharma's TOLSURA presented at IDWeek 2020
26/10/20		201.14KB	Share
MYX Lapse of rights and AGM Notice of Meeting clarification
23/10/20		183.73KB	Share
MYX Becoming a substantial holder
14/10/20		680.76KB	Share
MYX 2020 Annual General Meeting
14/10/20		1.61MB	Share
MYX Appendix 4G
08/10/20		240.06KB	Share
MYX 2020 Corporate Governance Statement
08/10/20		559.51KB	Share
MYX Annual Report to shareholders
08/10/20		3.76MB	Share
MYX Mayne Pharma provides update on Women's Health pipeline
06/10/20	PRICE SENSITIVE	153.98KB	Share
MYX Appendix 3G
29/09/20		215.73KB	Share
MYX Mayne Pharma appoints new CFO
29/09/20		112.88KB	Share
MYX Appendix 3G
22/09/20		715.91KB	Share
MYX Change of Director's Interest Notice
02/09/20		199.03KB	Share
MYX Change of Director's Interest Notice
01/09/20		203.1KB	Share
MYX Ceasing to be a substantial holder
25/08/20		533.4KB	Share
MYX Change in substantial holding
24/08/20		946.03KB	Share
MYX 2020 Full Year Investor Presentation
21/08/20	PRICE SENSITIVE	6.13MB	Share
MYX 2020 Full Year Media Release
21/08/20	PRICE SENSITIVE	404.79KB	Share
MYX Appendix 4E and Statutory Accounts
21/08/20	PRICE SENSITIVE	1.59MB	Share
MYX Change in substantial holding
07/07/20		922.46KB	Share
MYX Mayne Pharma announces strategic partnership with Novast
06/07/20	PRICE SENSITIVE	158.24KB	Share
MYX MYX announces FDA filing acceptance of E4/DRSP in the US
24/06/20	PRICE SENSITIVE	149.82KB	Share
MYX Lapse of unlisted employee performance rights
15/06/20		167.92KB	Share
MYX S&P DJI Announces June 2020 Quarterly Rebalance
12/06/20	PRICE SENSITIVE	223.16KB	Share
MYX Becoming a substantial holder
03/06/20		405.74KB	Share
MYX Ceasing to be a substantial holder
01/06/20		406.72KB	Share
MYX MYX signs license agreement for contraceptive in Australia
28/05/20	PRICE SENSITIVE	150.15KB	Share
MYX Becoming a substantial holder
25/05/20		433.44KB	Share
MYX Mayne Pharma submits NDA for E4/DRSP to the FDA
16/04/20	PRICE SENSITIVE	121.21KB	Share
MYX Change of CFO and Company Secretary
20/03/20		150.13KB	Share
MYX Change in substantial holding
16/03/20		265.86KB	Share
MYX Change of Director's Interest Notice
11/03/20		205.02KB	Share
MYX Change of Director's Interest Notice
03/03/20		205.27KB	Share
MYX Lapse of employee options and rights
02/03/20		163.09KB	Share
MYX 2020 Half Year Investor Presentation
21/02/20	PRICE SENSITIVE	3.5MB	Share
MYX 2020 Half Year Media Release
21/02/20	PRICE SENSITIVE	325.33KB	Share
MYX Half Yearly Report and Accounts
21/02/20	PRICE SENSITIVE	1.11MB	Share
MYX Change of Director's Interest Notice
09/01/20		276.03KB	Share
MYX Change of Director's Interest Notice
09/12/19		284.37KB	Share
MYX Employee LTI changes and Appendix 3B
09/12/19		422.23KB	Share
MYX Final Director's Interest Notice
25/11/19		88.42KB	Share
MYX Results of Meeting
22/11/19		165.85KB	Share
MYX 2019 AGM Presentation
22/11/19		705.16KB	Share
MYX 2019 AGM CEO's Speech
22/11/19	PRICE SENSITIVE	138.92KB	Share
MYX 2019 AGM Chairman's Address
22/11/19		116.24KB	Share
MYX Mayne Pharma continues expansion of dermatology pipeline
19/11/19		103.55KB	Share
MYX Mayne Pharma completes E4/DRSP transaction and Appendix 3B
13/11/19		346.94KB	Share
MYX E4/DRSP contraceptive presented at EU gynecology conference
23/10/19	PRICE SENSITIVE	110.39KB	Share
MYX Retirement of Director
21/10/19		102.92KB	Share
MYX Notice of Annual General Meeting/Proxy Form
21/10/19		748.91KB	Share
MYX Change of Director's Interest Notice (x2)
18/10/19		200.5KB	Share
MYX Appendix 4G and Corporate Governance Statement
14/10/19		456.52KB	Share
MYX 2019 Annual Report
14/10/19		2.93MB	Share
MYX Appendix 3B
03/10/19		294.07KB	Share
MYX MYX signs license agreement for novel oral contraceptive
02/10/19	PRICE SENSITIVE	126.01KB	Share
MYX Appendix 3B
30/09/19		296.05KB	Share
MYX Lapse of employee options
16/09/19		160KB	Share
MYX PBS listing for KAPANOL in chronic breathlessness
27/08/19		120.89KB	Share
MYX 2019 Full Year Results Investor Presentation
23/08/19	PRICE SENSITIVE	1.14MB	Share
MYX 2019 Full Year Results Media Release
23/08/19	PRICE SENSITIVE	174.98KB	Share
MYX Appendix 4E and Full Year Statutory Accounts
23/08/19	PRICE SENSITIVE	1.71MB	Share
MYX Change in substantial holding
30/07/19		249.4KB	Share
MYX Lapse of employee options
04/07/19		152.94KB	Share
MYX Change in substantial holding
21/05/19		159.5KB	Share
MYX Mayne Pharma market update
14/05/19	PRICE SENSITIVE	286.05KB	Share
MYX Mayne Pharma investor presentation to Goldmans conference
04/04/19		5.02MB	Share
MYX Change in substantial holding
14/03/19		342.74KB	Share
MYX 2019 Half Year Investor Presentation
22/02/19	PRICE SENSITIVE	1.44MB	Share
MYX 2019 Half Year Media Release
22/02/19	PRICE SENSITIVE	439.98KB	Share
MYX Half Year Accounts
22/02/19	PRICE SENSITIVE	1.44MB	Share
MYX Mayne Pharma announces new indication for Kapanol by TGA
19/02/19		419.43KB	Share
MYX Lexette (halobetasol) foam now launched in the US
13/02/19		257.82KB	Share
MYX Tolsura (SUBA-itraconazole) capsule now launched in the US
30/01/19	PRICE SENSITIVE	455.75KB	Share
MYX Change of Director's Interest Notice
31/12/18		323.39KB	Share
MYX Employee option exercise
28/12/18		251.6KB	Share
MYX Change of Director's Interest Notice
24/12/18		354.14KB	Share
MYX MYX extends debt facility and adds receivables facility
20/12/18		262.93KB	Share
MYX MYX announces US commercial rights for SUBA-itra in BCCNS
18/12/18		413.5KB	Share
MYX Ceasing to be a substantial holder
14/12/18		19.36KB	Share
MYX FDA approval of Tolsura (SUBA-itraconazole) capsules
12/12/18	PRICE SENSITIVE	409.5KB	Share
MYX Change of Director's Interest Notice
10/12/18		759.78KB	Share
MYX Appendix 3B
07/12/18		412.44KB	Share
MYX Becoming a substantial holder
06/12/18		164.69KB	Share
MYX Final Director's Interest Notice
29/11/18		720.26KB	Share
MYX Results of 2018 AGM
29/11/18		386.07KB	Share
MYX 2018 AGM CEO's Speech
29/11/18	PRICE SENSITIVE	256.36KB	Share
MYX 2018 AGM Chairman's Address
29/11/18	PRICE SENSITIVE	257.21KB	Share
MYX Appendix 3B
31/10/18		693.61KB	Share
MYX Retirement of Director
29/10/18		246.73KB	Share
MYX Notice of Annual General Meeting / Proxy Form
29/10/18		2.75MB	Share
MYX Investor Presentation Acquisition of halobetasol foam
26/10/18		660.17KB	Share
MYX MYX announces acquisition of FDA approved halobetasol foam
26/10/18		425.89KB	Share
MYX Appendix 4G and 2018 Corporate Governance Statement
19/10/18		1.22MB	Share
MYX 2018 Annual Report
12/10/18		5.1MB	Share
MYX Appendix 3B, employee option exercise and option lapse
10/10/18		1.02MB	Share
MYX Change in substantial holding
09/10/18		253.66KB	Share
MYX Appendix 3B, employee option exercise and option lapse
11/09/18		816.24KB	Share
MYX Change in substantial holding
31/08/18		354.01KB	Share
MYX 2018 Full Year Results Investor Presentation
24/08/18	PRICE SENSITIVE	1.43MB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last $4.68		Change -0.050(1.06%)		Mkt cap ! $398.1M

Open	High	Low	Value	Volume
$4.67	$4.76	$4.65	$606.2K	128.8K

Buyers (Bids)

No.	Vol.	Price($)
1	48	$4.68

Sellers (Offers)

Price($)	Vol.	No.
$4.70	105	1

View Market Depth

No.	Vol.	Price($)
1	48	4.680
3	3637	4.660
3	9938	4.650
2	794	4.640
1	105	4.630

Price($)	Vol.	No.
4.700	105	1
4.710	105	1
4.720	794	2
4.730	794	2
4.740	794	2

Last trade - 16.10pm 22/07/2024 (20 minute delay)


Last $4.69		Change -0.050 ( 0.52 %)
Open	High	Low	Volume
$4.62	$4.76	$4.62	29282
Last updated 15.59pm 22/07/2024 ?

MYX (ASX) Chart

MAYNE PHARMA GROUP LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories